1-1 of 1
Karen Maegley
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy

Bruno Gomes, Gregory Driessens, Derek Bartlett, Danying Cai, Sandra Cauwenberghs, Stefano Crosignani, Deepak Dalvie, Sofie Denies, Christopher P. Dillon, Valeria R. Fantin, Jie Guo, Marie-Claire Letellier, Wenlin Li, Karen Maegley, Reece Marillier, Nichol Miller, Romain Pirson, Virginie Rabolli, Chad Ray, Nicole Streiner, Vince R. Torti, Konstantinos Tsaparikos, Benoit J. Van den Eynde, Martin Wythes, Li-Chin Yao, Xianxian Zheng, Joseph Tumang, Manfred Kraus
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (12): 2530–2542.
https://doi.org/10.1158/1535-7163.MCT-17-1104
Published: 03 December 2018
View article titled, Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
Open the PDF for Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy in another window
Includes: Supplementary data